BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 31337055)

  • 1. Impact of Tumour Hypoxia on Evofosfamide Sensitivity in Head and Neck Squamous Cell Carcinoma Patient-Derived Xenograft Models.
    Harms JK; Lee TW; Wang T; Lai A; Kee D; Chaplin JM; McIvor NP; Hunter FW; Macann AMJ; Wilson WR; Jamieson SMF
    Cells; 2019 Jul; 8(7):. PubMed ID: 31337055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma.
    Jamieson SM; Tsai P; Kondratyev MK; Budhani P; Liu A; Senzer NN; Chiorean EG; Jalal SI; Nemunaitis JJ; Kee D; Shome A; Wong WW; Li D; Poonawala-Lohani N; Kakadia PM; Knowlton NS; Lynch CR; Hong CR; Lee TW; Grénman RA; Caporiccio L; McKee TD; Zaidi M; Butt S; Macann AM; McIvor NP; Chaplin JM; Hicks KO; Bohlander SK; Wouters BG; Hart CP; Print CG; Wilson WR; Curran MA; Hunter FW
    JCI Insight; 2018 Aug; 3(16):. PubMed ID: 30135316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical relevance and therapeutic predictive ability of hypoxia biomarkers in head and neck cancer tumour models.
    Lee TW; Singleton DC; Harms JK; Lu M; McManaway SP; Lai A; Tercel M; Pruijn FB; Macann AMJ; Hunter FW; Wilson WR; Jamieson SMF
    Mol Oncol; 2024 Mar; ():. PubMed ID: 38426642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in nasopharyngeal carcinoma in vitro and in vivo.
    Huang Y; Tian Y; Zhao Y; Xue C; Zhan J; Liu L; He X; Zhang L
    Cancer Commun (Lond); 2018 May; 38(1):15. PubMed ID: 29764490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The hypoxia-activated prodrug evofosfamide in combination with multiple regimens of radiotherapy.
    Nytko KJ; Grgic I; Bender S; Ott J; Guckenberger M; Riesterer O; Pruschy M
    Oncotarget; 2017 Apr; 8(14):23702-23712. PubMed ID: 28423594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deep-learning and MR images to target hypoxic habitats with evofosfamide in preclinical models of sarcoma.
    Jardim-Perassi BV; Mu W; Huang S; Tomaszewski MR; Poleszczuk J; Abdalah MA; Budzevich MM; Dominguez-Viqueira W; Reed DR; Bui MM; Johnson JO; Martinez GV; Gillies RJ
    Theranostics; 2021; 11(11):5313-5329. PubMed ID: 33859749
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparison of hypoxia-activated prodrug evofosfamide (TH-302) and ifosfamide in preclinical non-small cell lung cancer models.
    Sun JD; Liu Q; Ahluwalia D; Ferraro DJ; Wang Y; Jung D; Matteucci MD; Hart CP
    Cancer Biol Ther; 2016 Apr; 17(4):371-80. PubMed ID: 26818215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypoxia-Activated Prodrug Evofosfamide Treatment in Pancreatic Ductal Adenocarcinoma Xenografts Alters the Tumor Redox Status to Potentiate Radiotherapy.
    Kishimoto S; Brender JR; Chandramouli GVR; Saida Y; Yamamoto K; Mitchell JB; Krishna MC
    Antioxid Redox Signal; 2021 Oct; 35(11):904-915. PubMed ID: 32787454
    [No Abstract]   [Full Text] [Related]  

  • 9. A phase 1 'window-of-opportunity' trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patients.
    Larue RT; Van De Voorde L; Berbée M; van Elmpt WJ; Dubois LJ; Panth KM; Peeters SG; Claessens A; Schreurs WM; Nap M; Warmerdam FA; Erdkamp FL; Sosef MN; Lambin P
    BMC Cancer; 2016 Aug; 16():644. PubMed ID: 27535748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anticancer efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in osteolytic breast cancer murine models.
    Liapis V; Zinonos I; Labrinidis A; Hay S; Ponomarev V; Panagopoulos V; Zysk A; DeNichilo M; Ingman W; Atkins GJ; Findlay DM; Zannettino AC; Evdokiou A
    Cancer Med; 2016 Mar; 5(3):534-45. PubMed ID: 26749324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of [18F]FMISO autoradiography and pimonidazole [corrected] immunohistochemistry in human head and neck carcinoma xenografts.
    Troost EG; Laverman P; Philippens ME; Lok J; van der Kogel AJ; Oyen WJ; Boerman OC; Kaanders JH; Bussink J
    Eur J Nucl Med Mol Imaging; 2008 Oct; 35(10):1803-11. PubMed ID: 18421457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor grafts derived from patients with head and neck squamous carcinoma authentically maintain the molecular and histologic characteristics of human cancers.
    Peng S; Creighton CJ; Zhang Y; Sen B; Mazumdar T; Myers JN; Lai SY; Woolfson A; Lorenzi MV; Bell D; Williams MD; Johnson FM
    J Transl Med; 2013 Aug; 11():198. PubMed ID: 23981300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticancer efficacy of the hypoxia-activated prodrug evofosfamide is enhanced in combination with proapoptotic receptor agonists against osteosarcoma.
    Liapis V; Zysk A; DeNichilo M; Zinonos I; Hay S; Panagopoulos V; Shoubridge A; Difelice C; Ponomarev V; Ingman W; Atkins GJ; Findlay DM; Zannettino ACW; Evdokiou A
    Cancer Med; 2017 Sep; 6(9):2164-2176. PubMed ID: 28799237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined Antitumor Therapy with Metronomic Topotecan and Hypoxia-Activated Prodrug, Evofosfamide, in Neuroblastoma and Rhabdomyosarcoma Preclinical Models.
    Zhang L; Marrano P; Wu B; Kumar S; Thorner P; Baruchel S
    Clin Cancer Res; 2016 Jun; 22(11):2697-708. PubMed ID: 26719428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TAM family receptors in conjunction with MAPK signalling are involved in acquired resistance to PI3Kα inhibition in head and neck squamous cell carcinoma.
    Ruicci KM; Meens J; Plantinga P; Stecho W; Pinto N; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Howlett CJ; Boutros PC; Ailles L; Nichols AC
    J Exp Clin Cancer Res; 2020 Oct; 39(1):217. PubMed ID: 33059733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PI3K Inhibitors Curtail MYC-Dependent Mutant p53 Gain-of-Function in Head and Neck Squamous Cell Carcinoma.
    Ganci F; Pulito C; Valsoni S; Sacconi A; Turco C; Vahabi M; Manciocco V; Mazza EMC; Meens J; Karamboulas C; Nichols AC; Covello R; Pellini R; Spriano G; Sanguineti G; Muti P; Bicciato S; Ailles L; Strano S; Fontemaggi G; Blandino G
    Clin Cancer Res; 2020 Jun; 26(12):2956-2971. PubMed ID: 31969334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Residual gammaH2AX foci in head and neck squamous cell carcinomas as predictors for tumour radiosensitivity: Evaluation in pre-clinical xenograft models and clinical specimens.
    Meneceur S; Löck S; Gudziol V; Hering S; Bütof R; Rehm M; Baumann M; Krause M; von Neubeck C
    Radiother Oncol; 2019 Aug; 137():24-31. PubMed ID: 31048234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional CRISPR and shRNA Screens Identify Involvement of Mitochondrial Electron Transport in the Activation of Evofosfamide.
    Hunter FW; Devaux JBL; Meng F; Hong CR; Khan A; Tsai P; Ketela TW; Sharma I; Kakadia PM; Marastoni S; Shalev Z; Hickey AJR; Print CG; Bohlander SK; Hart CP; Wouters BG; Wilson WR
    Mol Pharmacol; 2019 Jun; 95(6):638-651. PubMed ID: 30979813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of P450 Oxidoreductase as a Major Determinant of Sensitivity to Hypoxia-Activated Prodrugs.
    Hunter FW; Young RJ; Shalev Z; Vellanki RN; Wang J; Gu Y; Joshi N; Sreebhavan S; Weinreb I; Goldstein DP; Moffat J; Ketela T; Brown KR; Koritzinsky M; Solomon B; Rischin D; Wilson WR; Wouters BG
    Cancer Res; 2015 Oct; 75(19):4211-23. PubMed ID: 26297733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IL-6 Inhibition With MEDI5117 Decreases The Fraction of Head and Neck Cancer Stem Cells and Prevents Tumor Recurrence.
    Finkel KA; Warner KA; Kerk S; Bradford CR; McLean SA; Prince ME; Zhong H; Hurt EM; Hollingsworth RE; Wicha MS; Tice DA; Nör JE
    Neoplasia; 2016 May; 18(5):273-281. PubMed ID: 27237319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.